4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-010520
Director sold 3,485 shares at $19.15 ($66,729)
- Director acquired 3,485 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Ballal Rahul D. · Director
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-04-04 | Exercise or conversion : show line 1 in the form 10b5-1 | +3,485 | $12.60 | $43,911 | 25,826 | D |
| 2024-04-04 | Sale : show line 2 in the form 10b5-1 | −3,485 | $19.15 | $66,729 | 22,341 | D |
| Open-market sales · 3,485 sh · avg $19.15 · $66,729 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-04-04 | Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (right to buy) | −3,485 | 62,420 | D |
Loading xslF345X05/form4-04092024_120438.xml…